Ocugen to Present at World Orphan Drug Congress USA 2020 Conference
22 July 2020 - 7:15AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to treat rare and underserved ophthalmic diseases, today
announced it will present at the World Orphan Drug Congress USA
2020 Conference, to be held virtually from August 24-27, 2020.
Rasappa Arumugham, PhD, Chief Scientific Officer of Ocugen, will
highlight Ocugen’s breakthrough modifier gene therapy platform as
part of the Next Generation Therapies Seminar.
Presentation Details:Date:
Monday, August 24, 2020Time: 1:00 PM (Eastern
Time)Website:
https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to treat rare and
underserved eye diseases. Our breakthrough modifier gene therapy
platform has the potential to treat multiple retinal diseases with
one drug – “one to many” and our novel biologic product candidate
aims to offer better therapy to patients with underserved diseases
such as wet age-related macular degeneration, diabetic macular
edema and diabetic retinopathy. For more information, please
visit https://ocugen.com/
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer
IR@Ocugen.com
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024